Atara Biotherapeutics, Inc. (ATRA) Stock Forecast
ATRA analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 4.33 / 5 from 3 analysts
- Price target
- $13.67 average of analyst targets
- Upside to target
- +48.9% from the latest close
- Next earnings
- November 11, 2026
- 52-week range
- $4.18 – $18.09
ATRA analyst ratings
3 analystsNumber of analysts at each rating.
ATRA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ATRA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.22 | −$0.33 | −$0.11 | −$0.32 | +31.2% | 2 |
| Current fiscal year (2026) | −$0.95 | −$1.27 | −$0.63 | $2.57 | −137.0% | 2 |
| Next fiscal year (2027) | $1.54 | $0.53 | $2.56 | −$0.95 | +262.6% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ATRA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $533,330 | $0 | $1.0M | −84.5% | 3 |
| Current fiscal year (2026) | $2.8M | $1.1M | $5.0M | −97.6% | 3 |
| Next fiscal year (2027) | $40.9M | $31.0M | $57.0M | +1,334.6% | 3 |
ATRA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ATRA revenue: reported and forecast
ATRA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.30 | −$0.20 | −$0.20 | −$0.33 | −$0.22 | −26.7% | 0 up · 1 down |
| Current fiscal year (2026) | −$1.23 | −$0.88 | −$0.88 | −$1.27 | −$0.95 | −22.8% | 0 up · 1 down |
| Next fiscal year (2027) | $1.64 | $1.27 | $1.27 | $1.56 | $1.54 | −5.6% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ATRA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ATRA beat in 7 of 12.
What analysts expect from ATRA
3 analysts cover Atara Biotherapeutics; their consensus rating is buy (4.33 on a 1–5 scale, where 5 is a strong buy). The average price target is $13.67, 48.9% above the latest close of $9.18. Analysts expect earnings of −$0.95 per share for 2026, −137.0% from a year earlier. For 2027 the average estimate is $1.54 per share on revenue of $40.9 million. Atara Biotherapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: ATRA income statement, ATRA key metrics, ATRA chart. See the ATRA stock overview for the latest quote and news.
ATRA forecast FAQ
What is Atara Biotherapeutics's price target?
The average analyst price target for Atara Biotherapeutics is $13.67, 48.9% above the latest close of $9.18.
Is Atara Biotherapeutics a buy, hold or sell?
Of 3 analysts covering Atara Biotherapeutics, 2 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Atara Biotherapeutics's EPS forecast?
Analysts forecast −$0.95 per share for 2026 (range −$1.27 to −$0.63); for 2027 the estimate is $1.54.
What is Atara Biotherapeutics's revenue forecast?
The average revenue estimate for 2026 is $2.8 million, growth of −97.6%; for 2027 it is $40.9 million.
When does Atara Biotherapeutics report earnings?
Atara Biotherapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
Does Atara Biotherapeutics usually beat earnings estimates?
Atara Biotherapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.